Phase I-II study of ftorafur and methyl-ccnu in advanced colorectal cancer
โ Scribed by Robert J. Belt; Ronald Stephens
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 316 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
The combination of Ftorafur (NSC-148958) and methyl-CCNU (NSC-95441) was evaluated in 36 patients with advanced colorectal cancer. The principle toxicities encountered were myelosuppression, gastrointestinal, and neurological. There were no complete responses and only 5/34 (14.7%) patients achieved a partial response. Methyl-CCNU and Ftorafur does not appear to be an effective combination in advanced adenocarcinoma of the colon and rectum.
๐ SIMILAR VOLUMES
Thirty-two patients with advanced, inoperable nonhematologic soft-tissue and osseous sarcomas were treated with Methyl CCNU administered via controlled intravenous infusion in doses of 130-170 mg/m2 every 6 weeks in a Phase I1 trial. All 28 evaluable patients were no longer responsive to adriamycin.
The effect of psychosocial counseling on tumor progression was studied in 96 cancer patients, who were no longer amenable to regular medical treatment. Patients were offered 12 session of individual experiential-existential counseling, each sessions lasting 1.5 to 2 hours. In addition patients parti
## Background: For advanced colorectal carcinoma, 5-fluorouracil (5-fu)-leucovorin is the best therapy available. to improve results, a variety of drugs were added, including cisplatin (cddp), sometimes with controversial results. the combination of cddp and etoposide (vp-16) has shown synergistic